Vivos Therapeutics (VVOS) investor relations material

Executive summary

• Revenue for Q1 2026 increased 70% year-over-year to $5.1 million, driven by the SCN acquisition and a strategic shift to a medical provider-focused model.

• Net loss widened to $7.8 million from $3.9 million in Q1 2025, reflecting higher general and administrative expenses, integration costs, and expansion-related one-time items.

• Management highlighted strong growth momentum, reduced customer acquisition costs, and ongoing integration of SCN.

• Cash and cash equivalents were $2.1 million at March 31, 2026, insufficient to fund operations for the next 12 months, raising substantial doubt about going concern status.

• Equity financings in Q1 2026 raised $6.8 million, but stockholders' equity remains below Nasdaq's minimum requirement, risking potential delisting.

Financial highlights

• Q1 2026 revenue: $5.1 million (up from $3.0 million in Q1 2025).

• Gross profit increased 103% year-over-year to $3.1 million, with gross margin improving to 60% from 50%.

• Net loss: $7.8 million (vs. $3.9 million prior year), with operating expenses rising to $9.7 million including $0.9 million in non-recurring professional fees.

• Cash used in operations: $6.0 million (vs. $3.8 million prior year).

• Total liabilities: $26.3 million as of March 31, 2026; stockholders’ equity was a deficit of $1.1 million.

Outlook and guidance

• Management expects the SCN acquisition and further provider collaborations to drive future revenue growth and aims to achieve positive cash flow, but acknowledges risk if revenue targets are not met.

• Additional acquisitions or alliances are being pursued to expand the business model and increase patient volume.

• Focus remains on increasing productivity, insurance reimbursement, and achieving cash flow positive operations.

• The company is actively seeking further financing and considering debt restructuring to meet Nasdaq equity requirements.